SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021).
Jaume Capdevila CastillónMa Auxiliadora GómezMónica GuillotDavid PáezCarles PericayMaria José SafontNoelia TarazonaRuth VeraJoana VidalJavier SastrePublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2022)
The management of localized rectal cancer requires a multidisciplinary approach to optimize outcomes, reduce morbidity and prevent under or overtreatments. While early stages may obtain benefit of local resections without any additional therapies, locally advanced rectal cancer becomes a challenge defining the better sequential strategy of surgery, radiotherapy and chemotherapy. The latest results of international phase III studies have positioned the total neoadjuvant therapy as a potential new standard of care in high risk rectal cancers, however, the best schedule is still not well defined.
Keyphrases
- rectal cancer
- locally advanced
- phase iii
- neoadjuvant chemotherapy
- phase ii study
- open label
- clinical trial
- healthcare
- quality improvement
- minimally invasive
- palliative care
- squamous cell carcinoma
- radiation therapy
- double blind
- phase ii
- early stage
- metabolic syndrome
- young adults
- atrial fibrillation
- weight loss
- pain management
- human health
- cell therapy
- study protocol
- affordable care act
- childhood cancer